$2.67
-0.13[-4.64%]
At close: Apr 22
$2.67
0[0.00%]
PreMarket: 4:58PM EDT
Aytu BioPharma
(NASDAQ:AYTU)Aytu BioPharma Stock (NASDAQ:AYTU), Analyst Ratings, Price Targets, Predictions
Aytu BioPharma Inc has a consensus price target of $10, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Maxim Group, HC Wainwright & Co., and HC Wainwright & Co. on August 9, 2023, May 31, 2023, and July 21, 2022. With an average price target of $10.33 between Maxim Group, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 287.02% upside for Aytu BioPharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aytu BioPharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/09/2023 | AYTU | Buy Now | Aytu BioPharma | $2.67 | 87.27% | Maxim Group | Naz Rahman | → $5 | Initiates | → Buy | Get Alert |
| 05/31/2023 | AYTU | Buy Now | Aytu BioPharma | $2.67 | 649.06% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2022 | AYTU | Buy Now | Aytu BioPharma | $2.67 | 124.72% | HC Wainwright & Co. | Vernon Bernardino | $220 → $120 | Maintains | Buy | Get Alert |
| 05/17/2022 | AYTU | Buy Now | Aytu BioPharma | $2.67 | 87.27% | Cantor Fitzgerald | Jennifer Kim | $220 → $100 | Maintains | Overweight | Get Alert |
| 04/28/2022 | AYTU | Buy Now | Aytu BioPharma | $2.67 | 311.99% | HC Wainwright & Co. | Vernon Bernardino | $480 → $220 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Aytu BioPharma (AYTU)?
The latest price target for Aytu BioPharma (NASDAQ: AYTU) was reported by Maxim Group on August 9, 2023. The analyst firm set a price target for $5.00 expecting AYTU to rise to within 12 months (a possible 87.27% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aytu BioPharma (AYTU)?
The latest analyst rating for Aytu BioPharma (NASDAQ: AYTU) was provided by Maxim Group, and Aytu BioPharma initiated their buy rating.
When was the last upgrade for Aytu BioPharma (AYTU)?
There is no last upgrade for Aytu BioPharma.
When was the last downgrade for Aytu BioPharma (AYTU)?
There is no last downgrade for Aytu BioPharma.
When is the next analyst rating going to be posted or updated for Aytu BioPharma (AYTU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating Aytu BioPharma (AYTU) correct?
While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a initiated with a price target of $0.00 to $5.00. The current price Aytu BioPharma (AYTU) is trading at is $2.67, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.